RemeGen's high P/S ratio, driven by current investor sentiment and future expectations, may be concerning given the company's less than stellar revenue forecasts. Unless conditions improve, these prices may not be reasonable.
Despite RemeGen's subdued revenue growth projections, it trades at a P/S ratio similar to the industry, suggesting investors may be less bearish than analysts. However, its weaker revenue outlook could risk a share price decline and pose a risk to shareholders.
$恒生指数(800000.HK)$plunge deepened unceasingly after midday. It once stumbled 620 pts or 3.9% to bottom at 15,245, hitting an over-14-month low; last at 15,320, down 545 pts or 3.4%, with a total turnover of $88.5 billion. Pharmaceuticals were sold off.$荣昌生物(09995.HK)$once collapsed 27.5% to $22.8; last at $24.9, down 21%. $三叶草生物-B(02197.HK)$nosedived 9.6% to $0.47, hitting record low.$维亚生物(01873.HK)$...
In FT's story, The commerce department is expected to place more than two dozen Chinese companies on the entity list on Thursday, including some involved in biotechnology. The news triggers the sell-off in Hong Kong. $药明生物(02269.HK)$$药明康德(02359.HK)$$三叶草生物-B(02197.HK)$$荣昌生物(09995.HK)$
荣昌生物股票讨论区
HSI Plunge Once Deepens to 620 Pts; Pharmas In Sell-off
Pharmaceuticals were sold off. $荣昌生物(09995.HK)$ once collapsed 27.5% to $22.8; last at $24.9, down 21%.
$三叶草生物-B(02197.HK)$ nosedived 9.6% to $0.47, hitting record low. $维亚生物(01873.HK)$ ...
The news triggers the sell-off in Hong Kong.
$药明生物(02269.HK)$$药明康德(02359.HK)$$三叶草生物-B(02197.HK)$$荣昌生物(09995.HK)$
暂无评论